Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 8.530 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Travere Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test May 02, 2023 Travere was testing a treatment for FSGS, a condition that causes kidney scarring. Via Investor's Business Daily Travere Therapeutics' Rare Kidney Disease Drug Disappoints In Phase 3 Study, Analyst Says Efficacy Trends Suggest Potential Path Forward May 02, 2023 Travere Therapeutics Inc (NASDAQ: TVTX) announced Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 02, 2023 Via Benzinga The Latest Analyst Ratings for Travere Therapeutics April 17, 2023 Via Benzinga Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch April 03, 2023 Via Benzinga 3 Up-and-Coming Growth Stocks to Buy Right Now March 25, 2023 These companies are small now but could grow much larger over time. Via The Motley Fool Could an FDA Approval Send This Stock Flying? March 01, 2023 Is now the time to load up on this struggling stock? Via The Motley Fool Travere Therapeutics's Return On Capital Employed Overview February 28, 2023 Via Benzinga Why Travere Therapeutics Stock Bolted Higher This Week February 23, 2023 A high-value regulatory approval lit a fire underneath the biotech's shares this week. Via The Motley Fool 3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing March 19, 2023 The high-flyers have soared to new heights and further gains could be up ahead. Via The Motley Fool Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside March 01, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 March 01, 2023 Via Benzinga Travere Therapeutics's Earnings Outlook February 22, 2023 Via Benzinga What 10 Analyst Ratings Have To Say About Travere Therapeutics February 22, 2023 Via Benzinga The Latest Analyst Ratings for Travere Therapeutics January 30, 2023 Via Benzinga 4 Analysts Have This to Say About Travere Therapeutics December 05, 2022 Via Benzinga Earnings Scheduled For February 23, 2023 February 23, 2023 Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. Via Benzinga Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 21, 2023 Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session February 21, 2023 Via Benzinga Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday February 21, 2023 U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. Via Benzinga Where Travere Therapeutics Stands With Analysts December 05, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 February 21, 2023 Via Benzinga Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment February 21, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session February 20, 2023 Via Benzinga The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February February 01, 2023 These two growth stocks might deliver enormous gains for shareholders this month. Via The Motley Fool February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More January 31, 2023 The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... Via Benzinga Stocks That Hit 52-Week Lows On Monday December 12, 2022 Monday saw 196 companies set new 52-week lows. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 December 14, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 December 05, 2022 Via Benzinga Stocks That Hit 52-Week Lows On Tuesday November 22, 2022 During Tuesday's trading, 160 companies set new 52-week lows. Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.